Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Lijun Zhang et al.|The Lancet|2014Cited by 4.7k
Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Joyce O’Shaughnessy, Vassiliki Karantza et al.|New England Journal of Medicine|2020Cited by 3.1k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Martine Piccart, Marion Procter et al.|The Lancet|2007Cited by 1.5k
Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast CancerMichael Untch, Gottfried E. Konecny|Journal of Clinical Oncology|2009Cited by 151
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightnessOtto Metzger, Daniel G. Stover, Katharine A. Collier et al.|npj Breast Cancer|2021Cited by 37